Messina

• A clinical study of MK-7240 for the treatment of Crohn’s disease (MK-7240-008) Recruiting
  2024-518296-56-00 5 2025-09-29 Crohn’s Disease
• The AIRTIVITY TM Study: A study to find out whether BI 1291583 helps people with bronchiectasis Recruiting
  2024-518589-29-00 5 2025-08-21 Bronchiectasis
• A Phase 3, Single-Arm, Multiple-Dose, Pharmacokinetic Comparability Trial Between TAK-881 and HYQVIA in Adults With Chronic Inflammatory Dem … Recruiting
  2024-517450-95-00 5 2025-06-23 Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)
• Long-term safety and efficacy study of riliprubart in participants with CIDP Recruiting
  2024-517032-22-00 5 2025-06-10 Immune system diseases.
• Toward personalized medicine to guide drug withdrawal in children with juvenile idiopathic arthritis in clinical remission: a randomized cli … Recruiting
  2024-514732-24-00 6 2025-04-28 Juvenile idiopathic arthritis
• An Adaptive, Dose-Ranging, Phase 2 Study of Eltrekibart Given Alone or in Combination with Mirikizumab for the Treatment of Adult Patients w … Recruiting
  2023-507853-13-00 4 2025-02-25 Ulcerative Colitis
• A multicenter, Phase II, open label, randomized trial evaluating the efficacy of Tedopi plus docetaxel or Tedopi plus nivolumab as second-li … Recruiting
  2024-518224-74-01 4 2025-02-07 metastatic non-small-cell lung cancer
• Phase 3 Study of Vedolizumab Subcutaneous in Pediatric Subjects With Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease Recruiting
  2023-503188-40-00 5 2025-01-06 Active Ulcerative Colitis or Crohn’s Disease
• Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects with Moderately to Severely Active Crohn's Dis … Recruiting
  2023-509618-12-00 5 2024-09-11 Crohn's Disease (CD)
• Efficacy and Safety of Vedolizumab Intravenous in Pediatric Chronic Pouchitis Recruiting
  2023-504773-20-00 5 2024-08-01 Active Chronic Pouchitis
• Crohn's Disease: Pharmacokinetics, Efficacy, and Safety of Risankizumab in Pediatric Subjects with Moderately to Severely Active Crohn's Dis … Recruiting
  2022-502050-14-00 5 2024-06-04 Crohn's disease
• A multi-center, open-label, phase 2 study of Elranatamab in patients with high-risk smoldering multiple myeloma Recruiting
  2023-505775-70-00 4 2024-04-08 High risk smoldering multiple myeloma
• Combined Dose-Finding and CV Outcomes Study with CSL300 (Clazakizumab) in Adult Subjects with ESKD Undergoing Dialysis (POSIBIL6ESKD). Recruiting
  2022-500273-14-00 10 2023-07-17 Atherosclerotic cardiovascular disease in patients with ESKD
• A randomized, non-comparative, phase II study investigating the best epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) s … Recruiting
  2024-518223-29-00 4 2020-03-10 Advanced or metastatic untreated EGFR mutation positive NSCLC
• Effect of nepafenac/dexamethasone fixed dose combination vs. its individual components (nepafenac and dexamethasone monotherapies) on postop … Recruiting
  2025-523367-38-00 5 2026-05-11 Postoperative inflammation after cataract surgery
• HF-POLARIS: A research study to look at how well NNC0487-0111 works compared to placebo in people with heart failure and obesity Recruiting
  2025-523717-29-00 5 2026-04-28 HFpEF or HFmrEF and obesity
• A Phase 3 Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children with Short Statur … Recruiting
  2025-523079-44-00 5 2026-04-15 Turner Syndrome (TS)
• TRITON-PN: A Phase 3 Study to Evaluate the Efficacy and Safety of Nucresiran in Patients with Hereditary Transthyretin Amyloidosis with Poly … Recruiting
  2025-522544-40-00 5 2026-03-27 Hereditary transthyretin-mediated amyloidosis with polyneuropathy
• A study to test how well PLENVU®, a bowel cleansing medicine, works in children and teenagers before they have a colonoscopy exam Recruiting
  2025-522046-42-00 5 2026-03-24 Colonic disease
• Effects of ziltivekimab on coronary atherosclerotic burden in patients with acute myocardial infarction Recruiting
  2024-520364-34-00 5 2026-02-23 Acute myocardial infarction
• A phase 2, randomized, double-blind study of S-606001 as an add-on to enzyme replacement therapy in patients with late-onset Pompe disease. Recruiting
  2025-522146-40-00 4 2026-02-12 Late-onset Pompe disease.
• ZENITH: Zilebesiran in Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk … Recruiting
  2025-522960-34-00 5 2026-02-09 Established cardiovascular disease
• A study to investigate efficacy and safety of teplizumab compared with placebo in participants 1 to 25 years of age with Stage 3 Type 1 Diab … Recruiting
  2024-519494-19-00 5 2025-12-22 Nutritional and metabolic diseases
• A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition Recruiting
  2025-520825-19-00 5 2025-12-16 IgAN is Primary Immunoglobulin A Nephropathy (IgAN) (also known as Ber

Showing 25–48 of 140 trials